Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

Stocks Settle Higher as Drug Makers and Chip Stocks Rally

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.41%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.18%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.28%. December E-mini S&P futures (ESZ25 ) rose +0.39%, and December E-mini Nasdaq futures...

Barchart

Trump Announces Pfizer Deal He Says Will Lower Certain Drug Prices

The Trump administration on Tuesday announced a deal granting Pfizer a three-year reprieve on planned tariffs as the pharmaceutical giant vowed to voluntarily lower the prices of unspecified drugs for US purchase.

International Business Times

Pfizer Becomes First Drugmaker To Join Trump's Price Cut Push

On Tuesday, Pfizer Inc. (NYSE:PFE) announced a historic agreement with the Trump Administration to ensure U.S. patients pay lower prices for their prescription medicines.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Trump Seals Explosive Pfizer Deal To Cut Drug Prices With New TrumpRx Platform

Donald Trump has struck a headline-grabbing deal with Pfizer to slash US drug prices, launching a TrumpRx platform that bypasses intermediaries and raises major questions over enforcement and patient impact.

International Business Times UK

Pfizer agrees to offer discounted drugs through new federal website, Trump announces

President also said that company would offer medications to Medicaid at ‘most favored nation’ pricing

The Guardian - US

Pfizer agrees to lower prescription drug costs for Medicaid in a deal with Trump

Drugmaker Pfizer has agreed to lower drug costs and invest $70 billion in U.S. manufacturing under a deal struck with President Donald Trump's administration

The Independent UK

Pfizer Shares Are Trading Higher Tuesday: What's Going On?

Pfizer, Inc. (NYSE:PFE) shares are trading higher on Tuesday after The Washington Post reported that President Donald Trump will announce a drug-pricing deal with the company.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Pfizer sued in US over contraceptive that women say caused brain tumours

US class action lawsuit alleges company failed to warn about risks of using contraceptive injection Depo-Provera

The Guardian - UK

Pfizer is Locking in New Growth Through a New Acquisition

Pfizer is undergoing a new acquisition, exposing it to the weight loss market and additional revenue growth potential, which isn't priced in yet.

MarketBeat

Pfizer Faces Court Over Depo-Provera Brain Tumor Claims

Pfizer Inc. (NYSE: PFE) faces mounting legal challenges over claims that its contraceptive injection Depo-Provera (DMPA) is linked to brain tumors, with a key court hearing set for late September that could determine whether affected women can pursue their cases in court.

Benzinga

Mercosur deal: Von der Leyen being probed for auto-deleting Macron's text

A text message sent by Emmanuel Macron to Ursula von der Leyen is at the centre of an investigation by the European Ombudsman.

Euronews

Asian shares trade mixed after US stocks set more records

Asian shares are trading mixed in the absence of key market-driving news in the region, after a seemingly relentless rally continued on Wall Street

The Independent UK

Metsera Stock Rockets After Pfizer's $7.3b — Should You Still Invest?

Metsera stock has soared after Pfizer announced a $7.3 billion acquisition, sparking investor buzz. Analysts are now weighing whether the biotech rally has more room to run or if buyers should stay cautious.

International Business Times UK

Pfizer eyes obesity drug market as it seals $4.9bn deal for Metsera

Pharma giant Pfizer is betting on obesity treatments as it looks for new markets following the success of its COVID-19 vaccine.

Euronews

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Pfizer Tries To Revitalize Obesity Portfolio With $5 Billion Matsera Deal

Pfizer Inc. (NYSE:PFE) on Monday agreed to acquire Metsera, Inc. (NASDAQ:MTSR) to accelerate the next generation of medicines for obesity and cardiometabolic diseases.

The Independent UK

Pfizer amps up push into obesity treatments with $4.9B deal for Metsera

Pfizer is doubling down on obesity treatments by spending $4.9 billion on the development-stage drugmaker Metsera

Barchart

Why the Recovery in Pfizer Stock Could Be Bigger Than Investors Expect

Pfizer is quietly laying the foundation for a new era of sustainable growth.

Benzinga

Pfizer Reportedly Nears Metsera Acquisition Deal: PFE Stock Climbs In Monday Pre-Market

Pfizer Inc. (NYSE:PFE) stock climbed 1.54% in Monday pre-market amid reports that the company on the verge of acquiring Metsera Inc. (NASDAQ:MTSR), a developer of anti-obesity drugs.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

The 5 Best Dividend Stocks to Buy for Steady Income in 2025

Here are five “set-and-forget” dividend stocks.

Benzinga

Blue Chip Stocks With Fat Dividends: Smart Buy Or Value Trap?

Investors love blue-chip stocks that pay fat dividends, but high yield alone doesn’t guarantee a safe income stream.

Benzinga

Pfizer, Moderna, BioNTech Stocks Tumble After Report Of Plan To Link COVID Vaccines To Child Deaths

Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump administration health officials intend to link the vaccines to 25 child deaths. This assertion is reportedly based on unverified submissions to the Vaccine…

Benzinga

Pfizer, BioNTech Roll Out COVID-19 Update That Boosts Antibodies 4-Fold In High-Risk Adults

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) reported topline Phase 3 results for their LP.8.1-adapted monovalent COMIRNATY (2025-2026 Formula) in high-risk adults.

The Conversation

We risk a deluge of AI-written ‘science’ pushing corporate interests – here’s what to do about it

Back in the 2000s, the American pharmaceutical firm Wyeth was sued by thousands of women who had developed breast cancer after taking its hormone replacement drugs. Court filings revealed the role of “dozens of ghostwritten reviews and commentaries published in medical journals and supplements being used to promote unproven benefits…

We Got This Covered

Donald Trump undermines his one lonely success that is apparently his one-way ticket to the Nobel Peace Prize

Looks like he is running out of things to destroy.

Benzinga

Florida Chooses 'Medical Freedom' As State Plans To End Vaccine Mandates, Even For Schools: Experts Warn Of 'Major Disaster' (CORRECTED)

Editor’s Note: This article has been updated to reflect the correct year-to-date performance of Moderna stock.

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Trump Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.